2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

American Journal of Medicine

Volumn 129, Issue 4, 2016, Pages 384-391

  Bangalore, Sripal ^a   Fayyad, Rana ^b   Kastelein, John J ^c   Laskey, Rachel ^b   Amarenco, Pierre ^d   Demicco, David A ^b   Waters, David D ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d SORBONNE UNIVERSITÉ   (France)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

LDL C targets; Percent reduction; Statins

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HEART ARREST; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ATHEROSCLEROSIS; BLOOD; MIDDLE AGED;

AGED; ATHEROSCLEROSIS; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SIMVASTATIN;

EID: 84949650419     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.10.024     Document Type: Article

References (14)

1. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 129 25 Suppl 2 2014 S1 S45
2. European Association for Cardiovascular Prevention & Rehabilitation Z. Reiner, A.L. Catapano, and et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
3. NICE Clinical Guideline 181. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Clinical Guideline Centre (UK). London, UK: National Institute for Health and Care Excellence; 2014.
4. D.D. Waters, J.R. Guyton, D.M. Herrington, and et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
5. J.C. LaRosa, S.M. Grundy, D.D. Waters, and et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
6. T.R. Pedersen, O. Faergeman, J.J. Kastelein, and et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
7. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, and et al. High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
8. C.P. Cannon, E. Braunwald, C.H. McCabe, and et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
9. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, and et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
10. J.A. de Lemos, M.A. Blazing, S.D. Wiviott, and et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
11. Cholesterol Treatment Trialists' (CTT) Collaborators B. Mihaylova, J. Emberson, and et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
12. S.M. Boekholdt, G.K. Hovingh, S. Mora, and et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials J Am Coll Cardiol 64 2014 485 494
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
14. S.M. Grundy, J.I. Cleeman, C.N. Merz, and et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239